business / news / / Seeking Alpha
Cheap semaglutide copies in India challenge Novo Nordisk, cut Eli Lilly’s lead.
Low-cost semaglutide copies are now widely available in India's obesity drug market.
KEY POINTS
- These generics are eroding Eli Lilly's early market lead in India.
- Novo Nordisk faces its first significant competition in India from these cheaper alternatives.
- The availability of generics is rapidly transforming India's obesity treatment landscape.
COMPANIES
Summarized by Newsio from Seeking Alpha. How we summarize →